Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipid-lowering strategies. Curr Opin Lipidology. 2012 Aug;23(4):271-81. doi: 10.1097/MOL.0b013e32835423d9
Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular comorbidities among dyslipidemic US adults aged 65 years or older, stratified by lipid-lowering medication use. Poster presented at the 31st Annual Meeting of the Society of General Internal Medicine; April 2008. Pittsburg, PA. [abstract] J Gen Intern Med. 2008 Apr; 23(Supplement 2):419.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.
Fortuny J, Agusti A. Secondary prevention of acute myocardial infarction: should oral anticoagulants and platelet antiaggregants be administered on a combined basis? Med Clin (Barc). 2003 Oct 4;121(11):433-5. doi: 10.1016 / S0025-7753 (03) 73977-3
Mines D, Fosnocht KM, Berlin JA, Strom BL. Can primary care physicians diagnose innocent heart murmurs? Presented at the 1999 22nd Annual Meeting of the Society for General Internal Medicine; May 1, 1999. San Francisco, CA. [abstract] J Gen Intern Med. 1999 Feb; 14(Suppl 2):113. doi: 10.1046/j.1525-1497.1999.1420005.x
Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. BJOG. 1996 May;103(Suppl 13):53-7.
Brotons C, Rué M, Rivero E, Pérez G. Tendencies of mortality from cardiovascular diseases in Catalonia: 1975-1992. Med Clin (Barc). 1993 Nov 13;101(16):604-8.